Literature DB >> 21596074

Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.

M L Visciano1, L Diomede, M Tagliamonte, M L Tornesello, V Asti, M Bomsel, F M Buonaguro, L Lopalco, L Buonaguro.   

Abstract

Elicitation of a potent and broadly neutralizing antibody response is the main goal of an effective preventive HIV-1 vaccine. It has been shown by us and others that the expression of Env glycoproteins on the surface of particulate structures, such as Virus-Like Particles (VLPs), could be a more efficient strategy to deliver conformational epitopes to the immune system. To this aim, VLPs expressing native HIV Env gp140 or gp41 glycoproteins have been produced in insect cells using a baculovirus expression system and characterized for appropriate protein expression. VLP-bound HIV gp140 glycoprotein showed the appropriate expression and trimeric conformation. Immunogenicity studies have been performed in BALB/C mice by intra-peritoneal administration and sera from immunized mice have been tested in ELISA assays, for their reactivity with HIV specific antigens, as well as in ex vivo neutralization assay. Sera from immunized animals showed a high reactivity with individual HIV proteins expressed in VLPs. Results of TZM-bl based neutralization assay show that combined sera from animals independently immunized with gp140- or full-length-gp41-expressing VLPs have an additive/synergistic effect in the neutralization activity of HIV pseudoviruses. In conclusion, novel VLPs expressing different HIV Env glycoproteins with native trimeric conformation have been generated, showing the induction of effective antibody response with neutralization activity in TZM-bl neutralization assay. These results confirm the effectiveness of VLPs as presentation and delivery system for conformational proteins and show the improved neutralization activity upon the combination of anti-sera elicited by different HIV envelope antigens, suggesting the possibility of broadening the spectrum of viral epitopes targeted by immune response.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596074     DOI: 10.1016/j.vaccine.2011.05.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.

Authors:  Luigi Buonaguro; Maria Tagliamonte; Maria Luisa Visciano; Hanne Andersen; Mark Lewis; Ranajit Pal; Maria Lina Tornesello; Ulf Schroeder; Jorma Hinkula; Britta Wahren; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2012-03-29

2.  Induction of HIV-blocking anti-CCR5 IgA in Peyers's patches without histopathological alterations.

Authors:  Claudia Pastori; Lorenzo Diomede; Assunta Venuti; Gregory Fisher; Jonathan Jarvik; Morgane Bomsel; Francesca Sanvito; Lucia Lopalco
Journal:  J Virol       Date:  2014-01-08       Impact factor: 5.103

3.  Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James E Robinson; Mary Barnes; Cristian Apetrei; James M Binley
Journal:  Virology       Date:  2014-05       Impact factor: 3.616

4.  Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.

Authors:  Carmen Álvarez-Fernández; Alberto Crespo Guardo; Javier García-Pérez; Felipe García; Julia Blanco; Laura Escribà-García; Jose Maria Gatell; Jose Alcamí; Montserrat Plana; Sonsoles Sánchez-Palomino
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

5.  Effects of adjuvants on IgG subclasses elicited by virus-like particles.

Authors:  Maria Luisa Visciano; Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  J Transl Med       Date:  2012-01-05       Impact factor: 5.531

6.  Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.

Authors:  Simon H Bridge; Sally A Sharpe; Mike J Dennis; Stuart D Dowall; Brian Getty; Donald S Anson; Michael A Skinner; James P Stewart; Tom J Blanchard
Journal:  Virol J       Date:  2011-09-07       Impact factor: 4.099

7.  Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate.

Authors:  Maria Luisa Visciano; Maria Tagliamonte; Guillaume Stewart-Jones; Leo Heyndrickx; Guido Vanham; Marianne Jansson; Anders Fomsgaard; Berit Grevstad; Meghna Ramaswamy; Franco M Buonaguro; Maria Lina Tornesello; Priscilla Biswas; Gabriella Scarlatti; Luigi Buonaguro
Journal:  J Transl Med       Date:  2013-07-08       Impact factor: 5.531

8.  A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patients.

Authors:  Chiara Brombin; Lorenzo Diomede; Daniela Tudor; Anne Sophie Drillet; Claudia Pastori; Elena Poli; Agostino Riva; Caterina Uberti-Foppa; Massimo Galli; Clelia Di Serio; Morgane Bomsel; Lucia Lopalco
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

9.  Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana.

Authors:  Sarah A Kessans; Mark D Linhart; Nobuyuki Matoba; Tsafrir Mor
Journal:  Plant Biotechnol J       Date:  2013-03-19       Impact factor: 9.803

10.  Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).

Authors:  Concetta Ragone; Carmen Manolio; Beatrice Cavalluzzo; Angela Mauriello; Maria Lina Tornesello; Franco M Buonaguro; Filippo Castiglione; Luigi Vitagliano; Emanuela Iaccarino; Menotti Ruvo; Maria Tagliamonte; Luigi Buonaguro
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.